Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV 26508, USA.
J Oncol. 2011;2011:542358. doi: 10.1155/2011/542358. Epub 2011 Jun 12.
Anaplastic thyroid cancer (ATC) is an uncommon malignancy of the thyroid. Only 1-2% of thyroid cancers are anaplastic, but the disease contributes to 14-50% of the mortality with a median survival of 3 to 5 months. Most patients diagnosed with this disease are 65 years of age or older. The incidence of anaplastic thyroid cancer is decreasing worldwide. Most patients present with a rapidly growing neck mass, dysphagia, or voice change. We performed a comprehensive literature search using PubMed focusing on the treatment of anaplastic thyroid cancer including historical review of treatment and outcomes and investigations of new agents and approaches. A total of sixteen chart review and retrospective studies and eleven prospective studies and/or clinical trials were reviewed. The current standard therapeutic approach is to consider the disease as systemic at time of diagnosis and pursue combined modality therapy incorporating cytoreductive surgical resection where feasible and/or chemoradiation either concurrently or sequentially. Doxorubicin is the most commonly used agent, with a response rate of 22%. Several new agents are currently under investigation. Referral of patients for participation in clinical trials is needed.
间变性甲状腺癌（ATC）是一种罕见的甲状腺恶性肿瘤。仅有 1-2%的甲状腺癌为间变性，但该病导致的死亡率占 14-50%，中位生存期为 3-5 个月。大多数诊断为这种疾病的患者年龄在 65 岁或以上。间变性甲状腺癌的全球发病率正在下降。大多数患者表现为快速生长的颈部肿块、吞咽困难或声音改变。我们使用 PubMed 进行了全面的文献检索，重点关注间变性甲状腺癌的治疗，包括治疗和结果的历史回顾，以及新药物和方法的研究。共回顾了十六项图表审查和回顾性研究，十一项前瞻性研究和/或临床试验。目前的标准治疗方法是在诊断时将疾病视为全身性疾病，并采用联合治疗方法，包括可行的细胞减灭性手术切除和/或同期或序贯放化疗。阿霉素是最常用的药物，反应率为 22%。目前正在研究几种新的药物。需要将患者转介参加临床试验。
